AGN – As an addendum to message #49037, it’s worth noting that, with the Inamed acquisition, AGN has strayed pretty far from its roots in ophthalmology. Hence it’s not really surprising that the company appears to have little interest in sirna-027.
Other than Botox, AGN’s therapeutic-pharmaceuticals business is utterly pedestrian. If you listen to an AGN CC these days, 90% or more of the discussion pertains to aesthetic medicine: breast implants, dermal fillers, the LapBand device and, of course, Botox. It’s not the same company anymore.
Market Data 
Markets 
AI
